More trouble for embattled EpiPen maker Mylan (MYL) . Two U.S. senators claim Mylan overcharged Medicaid for some twenty years to the tune of millions of dollars. The lawmakers say the EpiPen was misclassified as a generic drug. That means Mylan was paying lower rebates to Medicaid, than if the drug was under the brand name category. Mylan came under intense scrutiny for raising the price of the life saving drug. TheStreet's Scott Gamm reports from Wall Street.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.